Cancer drug safety under review in japan
NCT ID NCT07527832
First seen Apr 19, 2026 · Last updated Apr 19, 2026
Summary
This study aims to check the safety of a cancer drug called bevacizumab (and its biosimilar version) when used by real patients with colorectal cancer in Japan. Researchers will look at the medical records of about 1,000 patients treated between 2019 and 2024 to see how often certain side effects, like bleeding or high blood pressure, occurred. The goal is to better understand the drug's safety profile in everyday medical practice, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.